Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMDSL4E)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
Azapropazone; APAZONE; Cinnopropazone; Prolixan; Azapropazonum; Azapropazona; Cinnamin; Rheumox; Sinnamin; Mitrolan; Azapropazon; Prolix; Xani; Azapropazone (anhydrous); 13539-59-8; AHR-3018; Prolixan 300; MI 85; AHR 3018; Apazone [USAN]; Azapropazon [German]; Mi-85; NSC-102824; Azapropazonum [INN-Latin]; Azapropazona [INN-Spanish]; NSC 102824; 5-(Dimethylamino)-9-methyl-2-propyl-1H-pyrazolo(1,2-a)(1,2,4)benzotriazine-1,3(2H)-dione; C16H20N4O2; 3-Dimethylamino-7-methyl-1,2-(n-propylmalonyl)-1,2-dihydro-1,2,4-benzotriazine; EINECS 236-9
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Breast
Breast adenocarcinoma
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||||||||||||||||||||
